Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Acrivon Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACRV
Nasdaq
8731
https://acrivon.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Acrivon Therapeutics Inc
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Mar 28th, 2024 12:00 pm
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
- Mar 5th, 2024 9:30 pm
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
- Mar 4th, 2024 1:00 pm
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
- Feb 27th, 2024 1:00 pm
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
- Feb 8th, 2024 1:00 pm
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 1:00 pm
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jan 12th, 2024 9:00 pm
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 4th, 2024 1:00 pm
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
- Jan 3rd, 2024 1:00 pm
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
- Nov 28th, 2023 1:00 pm
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
- Nov 21st, 2023 1:00 pm
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Nov 21st, 2023 1:00 pm
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Nov 9th, 2023 1:01 pm
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 16th, 2023 12:00 pm
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
- Oct 14th, 2023 1:02 pm
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Sep 19th, 2023 8:32 pm
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
- Sep 5th, 2023 8:05 pm
Acrivon Therapeutics to Participate in Two Investor Conferences in September
- Aug 30th, 2023 12:00 pm
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
- Aug 11th, 2023 11:00 am
Q2 2023 Akoya Biosciences Inc Earnings Call
- Aug 8th, 2023 4:38 pm
Scroll